Unknown

Dataset Information

0

Nusinersen Modulates Proteomics Profiles of Cerebrospinal Fluid in Spinal Muscular Atrophy Type 1 Patients.


ABSTRACT: Spinal muscular atrophy (SMA) type 1 is a severe infantile autosomal-recessive neuromuscular disorder caused by a survival motor neuron 1 gene (SMN1) mutation and characterized by progressive muscle weakness. Without supportive care, SMA type 1 is rapidly fatal. The antisense oligonucleotide nusinersen has recently improved the natural course of this disease. Here, we investigated, with a functional proteomic approach, cerebrospinal fluid (CSF) protein profiles from SMA type 1 patients who underwent nusinersen administration to clarify the biochemical response to the treatment and to monitor disease progression based on therapy. Six months after starting treatment (12 mg/5 mL × four doses of loading regimen administered at days 0, 14, 28, and 63), we observed a generalized reversion trend of the CSF protein pattern from our patient cohort to that of control donors. Notably, a marked up-regulation of apolipoprotein A1 and apolipoprotein E and a consistent variation in transthyretin proteoform occurrence were detected. Since these multifunctional proteins are critically active in biomolecular processes aberrant in SMA, i.e., synaptogenesis and neurite growth, neuronal survival and plasticity, inflammation, and oxidative stress control, their nusinersen induced modulation may support SMN improved-expression effects. Hence, these lipoproteins and transthyretin could represent valuable biomarkers to assess patient responsiveness and disease progression.

SUBMITTER: Bianchi L 

PROVIDER: S-EPMC8122268 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Nusinersen Modulates Proteomics Profiles of Cerebrospinal Fluid in Spinal Muscular Atrophy Type 1 Patients.

Bianchi Laura L   Sframeli Maria M   Vantaggiato Lorenza L   Vita Gian Luca GL   Ciranni Annamaria A   Polito Francesca F   Oteri Rosaria R   Gitto Eloisa E   Di Giuseppe Fabrizio F   Angelucci Stefania S   Versaci Antonio A   Messina Sonia S   Vita Giuseppe G   Bini Luca L   Aguennouz M'hammed M  

International journal of molecular sciences 20210421 9


Spinal muscular atrophy (SMA) type 1 is a severe infantile autosomal-recessive neuromuscular disorder caused by a survival motor neuron 1 gene (<i>SMN1</i>) mutation and characterized by progressive muscle weakness. Without supportive care, SMA type 1 is rapidly fatal. The antisense oligonucleotide nusinersen has recently improved the natural course of this disease. Here, we investigated, with a functional proteomic approach, cerebrospinal fluid (CSF) protein profiles from SMA type 1 patients wh  ...[more]

Similar Datasets

| S-EPMC10607664 | biostudies-literature
| S-EPMC9828332 | biostudies-literature
2020-01-07 | PXD016757 | Pride
| S-EPMC8390404 | biostudies-literature
| S-EPMC9544362 | biostudies-literature
| S-EPMC11387582 | biostudies-literature
| S-EPMC8351459 | biostudies-literature
| S-EPMC9306995 | biostudies-literature
| S-EPMC9932014 | biostudies-literature